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1. Introduction
Unlike most other industries, strict regulatory oversight exists in the 
medical device industry primarily to mitigate against potential risks 
to human health. Regulation obliges medical device companies to 
prove efficacy an d sa fe ty of  th ei r pr od ucts (T obin & Wa ls h, 2011), 
before being permitted market entry. Thus, for medical device com-
panies, gaining and maintaining regulatory compliance is essential 
and synonymous with market access and ongoing trade viability but 
expensive, time-consuming and risky (Engberg & Altmann, 2015). 
In today’s fast-paced, dynamic and highly competitive marketplace, 
only companies able to innovate rapidly will survive (Collyer, Bakal, 
& Verma, 2013). It is vital, therefore, that medical device companies 
learn how to manage regulatory and innovative demands simulta-
neously, for their sake and for the economies and patients they serve. 
However, we find little direction exists to guide medical device com-
panies on how to manage their regulatory obligations during new 
product development (NPD). Furthermore, of the regulatory infor-
mation that does exist, Engberg and Altmann (2015) explain that 
“manufacturers often h ave p roblems n avigating t he r egulatory t ext.” 
Thus, while the extant literature is rich in prescriptive regulatory 
information (e.g. routes to regulatory compliance; how regulations 
impact innovation etc.), there is scant empirical evidence to support 
medical device companies in the management of regulation-bound 
technology innovation (Medina, Kremer, & Wysk, 2013), despite the 
necessity of regulatory compliance to gain and maintain marketing 
approval. Additionally, the medical device industry is highly compe-
titive and historically slow to share its modus operandi. Despite this, 
the medical device industry provides the ideal backdrop to explore 
new product development (NPD) in a strictly regulated environment 
to provide industry and context-specific data.
The overarching research goal, therefore, is to provide exploratory, 
context-rich, empirical data where currently it is lacking and frag-
mented. To this end, and we believe for the first time in the litera-
ture, we posed questions directly to stakeholders of medical device 
development (MDD), namely regulatory affairs, quality assurance, 
and marketing specialists about three, regulation-controlled, product 
development activities, crucial to MDD and concomitantly to the 
acquisition and ongoing retention of regulatory approval; 1. Defining 
the product ‘intended use(s),’ 2. Defining product ‘marketing claims,’ 
3. Conducting ‘post-marketing surveillance.’ Furthermore, building
upon the extensive body of literature in non-regulated new product
development (NPD), we identified five recurring themes (Table 1),
widely accepted as drivers of successful NPD, (‘culture,’ ‘strategy for
regulation,’ ‘commitment,’ ‘organisation of teams,’ and ‘process’) to
examine their influence on medical device development (MDD).
Preliminary interviews with experts in regulation and MDD, in con-
junction with the literature, helped us to establish a framework (Table 
2) that guided development of a 40-item questionnaire.
Overall, we believe this study contributes valuable, new empirical in-
sights that will help progress understanding and thus management of 
vital industries where increasing regulatory controls exist, and it pro-
vides practical guidelines for more efficient management of medical 
device innovations.  
Since this research builds upon learnings from NPD research, an 
outline follows of the literature on five key themes driving NPD. We 
adapt these themes to the regulatory context of MDD to provide an 
explanation of our study framework. Next, we present the methodo-
logy, findings, and discuss our data analyses making recommenda-
tions for management. We conclude the paper with contributions. 
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2. Literature on New Product Development (NPD) and
Themes of Success
The extant literature in NPD covering over forty years’ research, es-
pouses five main themes drive successful NPD, namely “Process, Or-
ganization, Strategy, Commitment by senior management, and Cultu-
re” (Table 1). However, little empirical data exists that is particular to 
the medical device industry. We incorporate and adapt NPD themes 
to the regulatory context of medical device development (MDD) to 
explain our study framework, and review them next.
2.1 The Process of new product development
The NPD process refers to the strict set of activities beginning with an 
innovative idea (concept phase) and culminating in a new product 
for the market (commercialization) (Sun & Wing, 2005). Khurana 
and Rosenthal (1998), describe the development process as a set of 
“distinct phases.” De Waal and Knott (2010), advocate the existence 
of a “high quality, rigorous new product process” is “one of the stron-
gest drivers of profitability.” The significance of a well organised de-
velopment process continues to be extolled (Cooper & Kleinschmidt, 
2007) and would be expected to apply equally to the regulated process 
of MDD (Collyer et al., 2013) as to the non-regulated process of NPD. 
Therefore, we investigated the MDD process.
Various models have been proposed but no consensus has yet been 
established. Models range from the simple (Holger, 2002), to the com-
plex (Pietzsch, Shluzas, Paté-Cornell, Yock, & Linehan, 2009). Based 
on the literature and our interviews with regulatory experts, we de-
veloped a simplified model (fig.1) which identifies six main phases to 
MDD. We used this model to target our questions to specific process
phases to enhance the value of our findings.
Figure 1. The Process Phases of Medical Device Development 
2.1.1 Intended use(s) and Marketing Claims
Two essential outputs of the heavily regulated MDD process are the 
product definitions of ‘intended use(s)’ (which describes the planned 
purpose(s) of the product), and ‘marketing claims’ (statements aimed 
at users in support of the product).  These definitions are conceptuali-
zed, refined and defined during the process of MDD and come under 
regulatory scrutiny (Tobin & Walsh, 2011). 
A critical challenge for manufacturers of regulated goods is that to 
meet regulation’s strict standards requires documented proof of 
product validity (product performs as it is planned to and for the 
purpose(s) it is intended) and product reliability (product performs 
consistently), (Tobin & Walsh, 2011). Consequently, designing defini-
tions of ‘intended use(s)’ requires great care, and assertions made by 
‘marketing claims’ must correspond with those of ‘intended use(s).’ 
Since these product definitions come under such strict regulatory 
control, their management would be expected to impact regulatory 
approval and innovative outcomes, however, no empirical data for 
this exists. Moreover, once regulatory approval has been given for a 
stated purpose, any alterations to the product requires renewed ap-
proval by regulatory authorities. No data exists that measures the im-
pact of such changes. In line with the literature in NPD, authors Fritz 
and Cardle (2012), Collyer et al. (2013), condone and indeed promote 
early phase definition of product characteristics, the earlier, the better 
for more efficient market access (Kumar & Addie, 2006; Tobin & Wal-
sh, 2011). We examine these activities. 
2.1.2 Post-marketing surveillance
A phase unique to that of regulated products is termed post-marke-
ting surveillance (fig.1), which describes activities conducted after 
market entry for the regulatory obligation and purpose of providing 
evidence of on-going product safety and effectiveness in the marke-
tplace (Tobin & Walsh, 2011). Controversy exists in the literature. 
Some demand stricter regulatory controls enforcing the industry to 
proactively gather post-marketing feedback to help predict potential 
hazards by incidents such as the de Puy faulty hip joints scandal and 
other failures (Dhruva & Redberg, 2012; Sorenson & Drummond, 
2014). Others argue that stricter regulation will impede innovation 
and delay patients gaining access to the newest and best treatment 
options (Gregory, Curfman, & Redberg, 2011; Kierkegaard & Kier-
kegaard, 2013). Kumar and Addie (2006) advise, customer feedback 
offers a powerful tool for measuring performance, “good and bad.” 
These facts offer a compelling argument for a closer examination of 
the MDD process paying particular attention to activities defining 
intended use(s), marketing claims, and post-marketing surveillance 
(Table 2).
2.2 Organisation 
The theme of organization describes an “organizational setting within 
which the new product development process is active” (Cooper & 
Kleinschmidt, 1995). It refers to teams of individuals who work to-
gether, led by an “empowered leader.” Planning of the work is stres-
sed, inter-team and cross-functional collaborations are encoura-
ged  (Sivasubramaniam, Liebowitz, & Lackman, 2012). Kumar and 
Addie (2006), stress that “employee involvement and management 
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attention ensured the ultimate success.”   Morgan (2012), descri-
bes how inter-team collaborations build company capability. Thus, 
the body of knowledge conveys the criticality of employees within 
organizations and across teams being able to work well together so 
that companies can acquire and expand their capabilities to drive 
NPD.   
In the medical device industry, the rapid development of new tech-
nologies incorporating complex entities has meant that, increasingly, 
cross-functional team collaborations are essential in their develop-
ment (Hede, Nunes, Ferreira, & Rocha, 2013). Individuals heretofore 
not used to working together, find themselves expected to co-operate 
and collaborate. The importance of good communication, trust in 
communication and opportunities for timely communications, are 
highlighted in the current literature. What is lacking are empirical 
data on relationships, communication, and levels of trust within and 
between teams involved in MDD. Our research seeks some of this 
data (Table 2).
2.3 Strategy
The literature is replete with references to the theme of strategy, a 
comprehensive review of which is beyond the scope of this paper. We 
conclude that a strategy for NPD describes a charter for NPD which 
directs the actions a company must take to achieve its goals for inno-
vation and match its innovation capabilities (Cooper & Kleinschmidt, 
2007; Teece, 2008). Possession of a clear and formalized strategy links 
with successful NPD (De Waal & Knott, 2010; Dodgson, Gann, & Sal-
ter, 2008). It must be clearly communicated and understood by em-
ployees (Holger, 2002). A corporate strategy for NPD “states a well-
defined role of NPD in the company’s overall strategy” (Cooper & 
Kleinschmidt, 2007), which makes the allocation of resources toward 
the strategy more likely (De Waal & Knott, 2010). 
Thus, we expect that the possession of a regulatory-strategy and one 
backed up in corporate strategy will support MDD. Our study tests 
for this in the medical device industry (Table 2). 
2.4 Commitment 
Cooper and Kleinschmidt (1995), describe senior management com-
mitment as senior management’s “involvement with and corporate 
commitment to new product development.” Sun and Wing (2005) say 
it is when senior management “wholeheartedly” supports NPD and 
“visibly demonstrates this support” through clear communication, 
good employee relationships and the provision of resources toward 
NPD. Cooper and Kleinschmidt (1995), provide early evidence that 
making senior management accountable for NPD and tying in their 
incentives to successful outcomes, enhances NPD success. 
Research indicates that the longer senior management holds res-
ponsibility for any project, the less likely they are to terminate that 
project (Jonas, 2010). On one hand, this could prove unhelpful if 
senior management becomes so deeply attached it fails to cull pro-
jects displaying signs of economic non-viability. On the other hand, 
senior management support can be powerful in holding off internal 
conflicts from negatively impacting the projects that they specifica-
lly back. A significant volume of literature exists which demonstrates 
that a lack of senior management support results in project failure 
(Easterby-Smith, Thorpe, & Jackson, 2008). In our study, we exami-
ne the commitment shown by senior management toward regulation 
during MDD (Table 2).
2.5 Culture 
Poolton and Barclay (1998) describe an innovation culture as one 
where “the will to innovate is enshrined in the corporate culture and 
forms the basis for innovation policies.” It is considered essential in 
driving NPD success (Baker & Sinkula, 2007). Senior management is 
expected to promote the company’s innovative culture by providing 
a product “champion,” supporting new ideas, encouraging creativity 
and rewarding risk taking, even if the outcome is failure (Rodriguez 
& Hechanova, 2014).
Some authors say an integral element of an innovative culture is the 
active collection and distribution to staff of performance measure-
ments (De Waal & Knott, 2010; Kumar & Addie, 2006). The theory is 
that employees who receive measures of performance become moti-
vated to take personal responsibility for their contribution to perfor-
mance (Morgan, 2012). We test for employees’ knowledge of regula-
tory performance (Table 2).
A unique source of performance information is available to medi-
cal device companies through the activities of vigilance (respon-
sive) and post-marketing surveillance (proactively sought) which 
provide direct customer feedback. Vigilance and post-marketing 
surveillance activities are also regulatory requisites in this industry. 
Feedback informs about users’ real-life experiences and thus reflects 
customers’ actual satisfaction or otherwise with the product in its 
market. This feedback can be very useful if it alerts an organiza-
tion to a problem that could escalate to something more serious. 
Similarly, positive customer feedback could encourage and enhance 
further innovations. We test for a culture that supports regulation 
during MDD (Table 2).
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Table 1. Five themes associated with successful new product development and quotes.
Theme Best Practice Statements / Quotations References
Process
Importance of a formal process
High quality, rigorous new product process 
Importance of robust design
A clear concept of the future product & its future markets [...] early in the NPD process
A clear definition of the product before development begins
Griffin 1997; Medina et al. 2013
De Waal & Knott 2010
Zapata & Cantu 2008
Kumar & Addie 2006
Ika et al. 2012 
Salomo et al. 2010; Holger 2002 
Organisation
Effective leaders/champions essential
Employee involvement & management attention ensures success
Cross-functional issues are most important in the early stage of NPD
It is essential to engage team members in the planning process to ensure ownership of 
the plan 
Griffin 1997; Lewrick 2009
Kumar & Addie 2006
Sun and Win 2005
Salomo et al. 2010
Asgary & Thamhain 2016
Strategy
Having a clear & shared vision/charter
It is imperative to have clear & specific strategies
A corporate strategy for NPD incorporates NPD into the company’s overall strategy
Strategy determines the most appropriate process design & complexity for the firm’s 
context & targets
A formalized NPD strategy correlates with improved performance 
Griffin 1997 Lester 1998
Cooper & Kleinschmidt 2010
Khang & Moe 2008
Lynn et al. 1999 
Dodgson et al. 2008 
De Waal & Knott 2010
Commitment
Provision of top management attention
Provision of sufficient resources
Senior management commitment is key prerequisite for success
Commitment to quality is continually emphasized by senior management
Griffin 1997; Lester 1998; Khang & Moe 
2008;  
Saloma et al. 2010
Rodriguez & Hechanova 2014
Poolton & Barclay 1998
Kumar & Addie 2006
Culture
An ethos that supports the entrepreneurial spirit
Rewards new ideas, permits risks to be taken
Encourages employee initiative
Knowledge of performance is essential
Management at all levels is accountable for achieving business, quality and compliance 
success
Cooper & Kleinschmidt 1995
Griffin 1997; Sun & Wing 2005
De  Waal & Knott 2010
Ulrich & Eppinger 2008 
George et al. 2007
3 Method
3.1 Survey design and target population
This exploratory study followed a two-phase, mixed-methods ap-
proach to data collection (Creswell, 2009; Dillman, 2007). During 
phase one, we conducted semi-structured interviews with regulatory 
specialists working in MDD, namely regulatory affairs and quality as-
surance. From these interviews, we identified constructs for the con-
tents of our questionnaire (Table 2). Next, we pre-tested and piloted 
the questionnaire among eight individuals to confirm its validity and 
reliability (Fink, 2013). 
In the second phase, we targeted a sample of 64 medical device com-
panies based in Ireland (for homogeneity) and across all size catego-
ries, small (<50 employees), medium (51-249 employees) and large 
(>250 employees), and involved in MDD and commercialization, 
thus necessitating regulatory approval. We sourced these companies 
through the Irish medical device association’s membership directory 
(IMDA, 2016), supplemented with an on-line search of each organi-
zation. We excluded companies described as training business, soft-
ware developer or supplier. 
We dispatched 128 personalized requests for participation in the re-
search, directing on-line questionnaires to the manager of two stake-
holders’ teams per company, namely, regulatory affairs and marketing. 
Employing best practice protocols (Saunders, 2012) to maximise res-
ponse rate, we made a phone call to each of the 64 targeted companies 
requesting these managers’ names, because, according to Sauermann 
and Roach (2013) “personalization increases the odds of responding 
by as much as 48%.” Through the process of snowballing or “response 
cascading” (Fink, 2013), we encouraged first contact respondents to 
ask their team colleagues to partake in the research. We assured anon-
ymity, and to motivate completion of the relatively long questionnaire 
we interspersed long questions with short ones, added a ‘progress bar’ 
and offered a small prize from a draw to all participants completing 
the survey and willing to submit their contact details. We sent the 
survey using an on-line link which we left open for fourteen days. We 
followed up direct contacts with a reminder e-mail on day ten, and 
used statistical packages to analyze the data retrieved.
Since respondents were unknown to us, it guaranteed no “participant 
or observer bias response” (Saunders, 2012). Furthermore, because 
we presented respondents with an identical set of carefully selected 
questions, the questionnaire in the current study is deemed valid and 
reliable (Pallant, 2010).  
3.2 Questionnaire design
We divided the questionnaire into seven categories (Table 2), five in-
tegral to the themes of our research, another to render sample back-
ground information (e.g. company size, years in role etc.), and one to 
collect various measures of performance. Some measures were inhe-
rent in the questionnaire by directly comparing responses to question 
sets (e.g. ‘ideal’ versus ‘actual’). We requested other measures using 
empirical queries sourced mostly from De Waal and Knott (2010). 
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Construct Description Rationale Reference                                                   
Theme 1 Process of MDD
Intended use(s) Determine phase when these product definitions are made
Early-phase definitions associate with best 
practice design & market satisfaction
Rochford & Rudelius 1997                        
Khurana & Rosenthal 1998                           
Kumar & Addie 2006
De Waal & Knott 2010
Tobin & Walsh 2011                 Fritz & 
Caudle 2012
Marketing Claims Determine phase when these product definitions are made
Early-phase definitions associate with best 
practice design & market satisfaction
Intended use(s)  & 
Marketing Claims
Determine how closely the definitions 
align or match 




Explore the emphasis on, and involve-
ment in post-marketing surveillance  
activities
Regulatory oversight demands post-market-
ing surveillance 
Tobin & Walsh 2011
Resnic and Normand 2012 Sorenson & 
Drummond 2014                    
Theme 2 Organization for regulation during MDD
Team size Determine satisfaction with team size Provision of adequate labour resources links with success 
Cooper & Kleinschmidt 1995;2007; 
Holger 2002
Input by teams Examine when teams become involved in development phases
Early-stage involvement promotes early 
product definitions; late-stage involvement 
affiliates with post-marketing surveillance 
Tobin & Walsh 2011 
Ulrich & Eppinger 2008
Santos et al. 2012 
Sorenson & Drummond 2014
The Impact of teams Examine the roles of teams during devel-opment phases
Cross-functional collaboration is necessary 
for making product definitions & for gather-
ing post-marketing surveillance info.
Tobin & Walsh 2011 
Ulrich & Eppinger 2008
Resnic & Normand 2012 
Medina et al. 2013
Levels of trust Examine levels of agreement & co-oper-ation between teams
Trust & communication are critical to effec-
tive collaboration
Kumar & Addie 2006
George et al. 2007
Tobin & Walsh 2011
Frequency of Meetings Examine frequency of intra-team & inter-team meetings
Regular meetings promote flow of informa-
tion & generate trust
Morgan 2012
Hede 2013
Theme 3 Strategy for regulation in MDD
Clearly defined & com-
municated goals
Determine how clearly regulatory strate-
gy is communicated & understood
Clearly communicated goals corresponds 
with success
Cooper & Kleinschmidt 1995 Griffin 
1997; Sun & Wing 2005
Corporate strategy Testing for presence of regulatory strate-gy backed up by corporate strategy
Whole company buy-in correlates with suc-
cess
Poolton & Barclay 1998
Holger 2002; Foster 2013
Theme 4 Commitment for regulation by Senior Management (SM)
Priority of regulation 
to Senior Management 
(SM)
Examine level of importance placed by 
SM on regulatory management issues
Backup by SM is a pre-requisite for success & 
is associated with better performance
Griffin 1997; Khurana & Rosenthal 
1998; Sun & Wing 2005; Drucker 2011; 
Foster 2013
Resources Determine team satisfaction with re-sources toward regulation
Senior management is responsible for re-
sources access and allocation
Cooper & Kleinschmidt 1995; 2007; 
Sun & Wing 2005
Khang & Moe 2008
Relationships Examine levels of trust & communica-tion with SM Good relationships foster effective teamwork
Cooper & Kleinschmidt 1995 Diallo 
& Thuillier 2005 Sivasubramaniam et 
al. 2012
Theme 5 Culture for regulation
Regulatory Knowledge Determine levels of knowledge respon-dents have regarding regulation
A culture provides the basis for policies - it is 
essential in driving success
Poolton & Barclay 1998
Cooper & Kleinschmidt 2007     
Strategy for regulation Determine if a regulatory strategy exists in the organization
Having a strategy or vision associates with 
success
Cooper & Kleinschmidt 1995
Lynn et al. 1999
Regulatory Perfor-
mance knowledge
Determine the culture for regulation 
performance results
Knowledge about performance, individual 
and team performance, links with success
Morgan 2012
Kumar & Addie 2006
Ulricht & Eppinger 2008
De Waal & Knott 2010
Table 2. Themes to Construct and Questionnaire Development
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Performance Measures




Identify actual vs. ideal phases for definition of intended use(s) 
& for definition of marketing claims 
Assess actual vs. ideal level of alignment vs. 
between intended use(s) & marketing claims 
Determine presence of post-marketing surveillance activities
Knowledge of performance is linked to 
success 
Early definition is associated with good 
practice
Close match is a prerequisite for regulato-
ry approval
Post-marketing surveillance contributes 
to performance & customer knowledge
Poolton & Barclay 1998 
Tobin & Walsh 2011
Collyer et al. 2013





Market approval rate within expected time interval
Rate market approval rejection/ delay
Length market approval delay in months 
Number products submitted/approved for market approval in 
previous year
Number new products commercialized in previous year
Percentage value of overall sales from newly approved products 
in previous year
Knowledge among employees of individ-
ual and company performance is linked 
to ownership, motivation & success
Kumar & Addie 2006
de Waal & Knott 2010
Tobin & Walsh 2011
Morgan 2012
4 Results
Our empirical findings identify some factors impacting MDD. At a gra-
nular level, we show that the earlier product definitions of intended use(s) 
and marketing claims are completed, and the better aligned they are with 
each other, the sooner regulatory approval and thus commercialization, 
are achieved. We find there is less emphasis on post-marketing survei-
llance than expected. We reveal insufficient engagement by marketing 
teams compared with regulatory affairs and quality assurance experts du-
ring early-phase, and late-phase MDD activities that impact regulatory 
approval rate, and we find that cross-functional team meetings are rare. 
At the holistic level, we demonstrate a significant correlation between 
possession of a strategy for regulation and ‘speed to market,’ and that 
‘speed to market’ is deemed the activity of greatest importance to senior 
management. Finally, we uncover a low level of tacit knowledge about a 
selection of regulation-specific performance measures. 
4.1 Sample demographics
The survey was despatched directly to a purposefully targeted sam-
ple of 128 managers, 50% in marketing and 50% in regulatory affairs 
(or in charge of regulatory affairs duties). The overall response rate 
was 45% represented by 57 individuals from similar numbers of small 
(<50; n= 20), medium (51-249; n=16) and large (>250; n=21) medical 
device companies. Respondents included 14 marketing, 21 regulatory 
affairs and 22 quality assurance specialists, the vast majority of whom 
had over 11 years’ experience in their specialty (fig.2). 
4.2 The process of MDD 
Due to the relatively low number of marketing specialist respondents, 
and since most (except 3) dropped out after answering the early back-
ground questions, most of our analyses include responses from the 21 
regulatory affairs and 22 quality assurance respondents. 
4.2.1 Intended use(s) definition
Most specialists in both regulatory affairs and quality assurance 
(Table 3), recommend early phase confirmation of intended use(s) 
definitions, namely during concept development and design phases, 
with an emphasis by regulatory affairs specialists on confirming de-
finitions during the first phase. However, in reality, intended use(s) 
definitions are often made during later developmental phases. A hig-
her percentage of regulatory affairs (90%) than quality assurance spe-
cialists (65%) achieve intended use(s) definitions during the earliest 
development phases.
Table 3. Preferred timing and actual timing of product definition - intended use(s). 
Preferred timing of 
intended use(s)  
definition by specialty Development 
Phase
Actual timing of  










76% 50% Concept  Development 33% 35%
24% 45% Design 57% 30%
- - Manufacture - 5%
- - Packaging, Label-ing, Advertising 9.5% 25%
- 2% Commercialization - 5%
4.2.2 Marketing claims definition
The majority of respondents (Table 4) support early phase definition 
of marketing claims, with an emphasis by regulatory affairs specialists 
on achieving these definitions by the end of the design phase. In re-
ality, marketing claims are often defined during later developmental 
phases. Again, a higher percentage of regulatory affairs (67%) than 
quality assurance specialists (40%) achieve earlier phase definitions.  
Figure 2. Respondent Role and Company Size.
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Table 4. Preferred timing and actual timing of product definitions –  
marketing claims. 
Preferred timing of mar-
keting claims definition by 
specialty Development 
Phase
Actual timing of market-










48% 40% Concept  Development 24% 25%
48% 30% Design 43% 15%






2% 5% Commercializa-tion - 10%
A closer analysis reveals that in 29% of the smallest companies and 
in 35% of the largest companies, marketing claims are defined as late 
as during the phase of packaging, labeling, and advertising. Interes-
tingly, 100% of marketing management respondents (though small in 
number) said that marketing claims should be defined by the end of 
the design phase at the latest.
4.2.3 Alignment between intended use(s) and marketing claims definitions
The vast majority (81%) of respondents believe that marketing claims 
and intended use(s) definitions should be ‘very’ closely aligned. More 
specifically, 95.2% of regulatory affairs specialists and 80% of quality 
assurance experts advocate preference for ‘very’ close alignment. 
Figure 3 shows that the level of alignment achieved in reality, is not as 
close as experts deem preferable.   Further analysis demonstrates that 
the closest alignments occur in the smallest and largest companies, 
which are also associated with the greatest proportion of regulatory 
affairs employees. Regulatory affairs respondents quote achievement 
of ‘very close’ alignment in 93.3% of cases, and only 6.7% report them 
to align ‘somewhat closely.’ By comparison, quality assurance specia-
lists describe achieving ‘very close’ alignment in only 50% of cases. 
4.2.4 Impact of product definitions inaccuracies on rate of  
commercialization
Respondents were asked about the delay caused to regulatory appro-
val achievement, by different product definition inaccuracies (1-4 be-
low). Pearson Chi-squared tests for correlations found associations of 
significance between “achieving clearance for market within the plan-
ned time-frame” (which is equivalent to achieving on-time regulatory 
approval) and each of the 4 product definition inaccuracies exami-
ned, namely; 
1. unclear intended use(s) definition (r = .476, N=41, p =.002),
2. missing data regarding intended use(s) definition (r = .402,
N=42, p = .008),
3. unclear marketing claims definition (r = .410, N=40, p = .009), 
4. missing data regarding marketing claims definition (r = .397,
N=41, p = .010)
All correlations were positive indicating that as the frequency of various 
inaccuracies increased, the frequency of gaining ‘on-time approval’ moved 
in the same direction from ‘always’ (1) to ‘never’/’don’t know’ (4/5) i.e. on-
time approval outcome decreases as delays are more regularly encountered.
Figure 3. Actual alignment between marketing claims and intended use(s).
4.2.5 Post-marketing surveillance 
Table 5 shows that regulatory affairs and quality assurance teams are 
involved in post-marketing activities 93% of the time where they 
make an impact 70% of the time. In contrast, respondents reported 
that marketing teams are involved in post-marketing surveillance 
47% of the time, making an impact only 40% of the time. Figure 4 in-
dicates that, in only 18.8% of cases, senior management place a ‘very 
high’ level of importance on post-marketing surveillance activities.
4.3 Organization for regulation during MDD
4.3.1 Engagement by teams - Involvement and Impact
Regulatory affairs and quality assurance teams demonstrate a greater 
level of involvement and make a greater impact in all developmen-
tal phases, except product launch, compared with that of marketing 
teams (Table 5). Marketing teams are involved in the earliest phases 
of concept development and design, 54% and 34% of the time res-
pectively, making an even smaller impact during those periods, 40% 
and 34% respectively. Marketing teams’ participation is highest du-
ring two development stages, product launch (82%) and packaging, 
labeling and advertising (73%), typically seen as marketing-specific 
responsibilities. The low levels involvement by marketing teams in 
post-marketing surveillance has already been highlighted.

















Involvement Involvement Impact Impact
81% 54% Concept  Development 43% 40%
91% 39% Design 66% 34%













Table 5. Involvement & impact levels of teams during MDD.
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4.3.2. Relationships, Trustworthiness, Communication  
and Meetings frequency
We examined the levels of trust and ease of communication felt by 
quality assurance and regulatory affairs respondents towards team co-
lleagues and cross-functional team members. Respondents expressed 
lower levels of trust with marketing teams than with senior manage-
ment or own team members.  Communication with senior manage-
ment showed a greater number who were ‘satisfied’, rather than ‘very’ 
or ‘highly’ satisfied. Few were ‘highly’ satisfied with communication 
between themselves and marketing teams. 
Neither inter-disciplinary nor cross-functional team meetings are 
held frequently. Cross-functional team meetings take place once a 
week according to only 20% of quality assurance and 29% of regu-
latory affairs respondents. 14% of regulatory affairs respondents said 
they hold cross-functional team meetings every two weeks. 45% of 
quality assurance respondents report monthly cross-functional team 
meetings or even less frequent.
4.4 Senior management support for regulation during MDD
4.4.1 Senior management emphasis of importance 
Figure 4 reveals respondents’ perception of senior management prio-
rities; its ‘highest’ level of importance attaches to achieving ‘speed 
to market’ (56.3%), and its ‘lowest’ to ‘post-marketing surveillance’ 
(18.8%). Furthermore, respondents reported that senior management 
attaches a ‘high’ to ‘very high’ level of importance on ‘return of inves-
tment in marketing’ (68.8%). 79.1% of respondents say senior mana-
gement places a ‘high’ to ‘very high’ level of importance on ‘meeting 
overall budgets.’
4.4.2 Resource allocation by senior management
Overall, respondents report a ‘high level of satisfaction’ (69.2%) with 
‘team size,’ and with ‘financial resources’ (65.2%), the greatest satisfac-
tion is in the largest companies. 
80% of respondents who are ‘dissatisfied’ with team size and budgets 
are quality assurance specialists. 
Figure 4. Senior management support per management activity.
4.4.3 Relationships with senior management
A robust relationship appears to exist between senior management, 
regulatory affairs, and quality assurance respondents; 75% describe 
senior management as ‘very’ or ‘highly’ ‘supportive,’ and report overall 
‘level of trustworthiness’ from ‘good’ to ‘very high’ in 93.5% of cases. 
The study reveals lower ‘levels of satisfaction’ with ‘communication bet-
ween teams’. Only 23.9% of respondents are ‘highly satisfied,’ 28.2% 
are ‘very satisfied.’ 
4.5 Regulatory strategy findings
The majority of respondent companies (87%) possess a regulatory 
strategy. In 76% of these cases, the regulatory strategy is backed up 
by corporate strategy. 
A Pearson’s Chi-Squared test reveals a medium but significant negati-
ve correlation (x²/r = -.332, N = 45, p = 0.026), reflecting an increasing 
frequency of achieving on-time approval associated with possession 
of a regulatory strategy (variable scores for frequency of achievement 
go from 1 = always to 5 = never, hence negative correlation). There 
is no association of significance between achieving on-time appro-
val and having the regulatory strategy supported by corporate strate-
gy. Further analysis shows that possession of a regulatory strategy is 
more likely in larger companies. 
Most respondents report that regulatory strategy goals are clear and 
well communicated to them. 56% of respondents declare regulatory 
objectives are ‘very clear,’ 28% claim they are ‘moderately clear’ and of 
these, 40% work in quality assurance.
4.5 Regulatory culture findings 
4.5.1 Regulatory knowledge 
Not surprisingly, the study shows that regulatory affairs specialists 
have the highest level of knowledge on regulatory matters. 95% say 
their ‘regulatory knowledge’ is ‘very good’ or ‘expert.’ 
Only 10% of quality assurance experts report an ‘expert’ level of regu-
latory knowledge, 45% say their regulatory knowledge is ‘very good,’ 
40% call it ‘good.’ 
None of the marketing personnel report an ‘expert’ level of regulatory 
knowledge.  
In order of ‘impact,’ respondents reported that regulation has its ‘lar-
gest impact’ on ‘safety’ and ‘quality’ followed by ‘reliability,‘ ‘effective-
ness,’ ‘speed to market,’ and interestingly, they see regulation having its 
‘least impact’ on product ‘cost.’ However, a notable finding is that only 
27.3% consider that regulation has its ‘greatest impact’ or its ‘second 
greatest impact’ on ‘speed to market.’
4.5.2 Regulation-related performance results 
Many respondents were unable to comment on the different perfor-
mance related queries posed, and the more empirical the questions, 
the higher the percent of ‘don’t know’ responses. Examples below;
On average, do new products attain market approval within the ex-
pected time-frame? ‘Don’t know’ (17%)
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On average, how many products were submitted for market approval 
in the last year? ‘Don’t know’ (39%)
On average, how many products were approved in the last year? ‘Don’t 
know’ (41%)
On average, how many newly-approved products were commerciali-
zed in the last year? ‘Don’t know’ (52%)
What was the average percent value of overall sales contributed by 
newly approved products in the last year? ‘Don’t know’ (83%).
Even when presented with some reasons (5) that might cause regu-
latory approval rejection or even delay, a third of respondents in re-
gulatory affairs and quality assurance could not say how frequently 
rejection resulted. On average, 55% could not even give an average 
length of delay in months.
5 Discussion
Operating within a strict regulatory context means that regulated in-
dustries face an everyday struggle with competing demands. On the 
one hand, a market that expects rapid innovation to provide its cus-
tomers with the newest technology at best price. On the other hand, 
regulatory oversight insists on precious and costly time investment 
to provide documented proof of product validity, efficacy, and safe-
ty, to gain permission to launch into and remain in the market. This 
conflict between the need to reach markets faster than the compe-
tition while simultaneously devoting adequate time to acquire and 
maintain regulatory compliance status, is an on-going yet critical cha-
llenge faced uniquely by regulation-controlled industry, and one not 
yet adequately addressed in the literature. Our study provides badly 
needed empiric insights into NPD in one highly regulated industry, 
the medical device industry in Ireland. Thus, we provide a more de-
tailed picture of the realities of innovation within a regulatory context 
and add to the body of awareness about MDD in Ireland, to assist the 
industry in managing MDD. 
5.1 Sample demographics 
The medical device industry is a difficult one from which to extract 
information, we are very satisfied with a response rate of 45% (57 res-
pondents). 
The study achieves a good balance in all company sizes (large, me-
dium, small), and of regulatory affairs and quality assurance specia-
lists. As a result, the study reveals some trends associated with com-
pany size and some associated with the respondents’ role. Moreover, 
since our respondent companies are all located in Ireland, we have a 
homogenous sample providing context-specific data. As such, we can 
make comparisons between companies since all are operating within 
the same economic and political environment. Also, our respondents 
have more than eleven years’ experience in their respective specialty 
making their responses more likely valid, e.g., Cooper and Kleinsch-
midt (1995) only accepted respondents into their research who had a 
minimum of 3 years’ experience. 
5.2 Activities associated with the process of MDD
The activities of defining product use(s) and marketing claims are 
process development activities within MDD that are central to crea-
ting and selling a new product’s identity. These activities are also cri-
tically analyzed as part of regulatory oversight. The activities of post-
marketing surveillance are a prerequisite of continued regulatory 
satisfaction, and the feedback produced has the potential to add to 
a company’s body of information on its customers and its products. 
Consequently, gaining deeper insight into these three regulation-con-
trolled process activities was pivotal in our research. 
5.2.1 Intended use(s) and Marketing claims 
In agreement with the literature that associates early phase product 
definitions with more successful NPD (Cooper & Kleinschmidt, 
2007; De Waal & Knott, 2010), our research supports a more closely 
integrated process for MDD. 
First, we find significant agreement among specialists that intended 
use(s) and marketing claims definitions should be confirmed prefe-
rably during the first and no later than the second phase of the MDD 
process. These respondents who are important stakeholders in regu-
lation, agree with a high degree of alignment between intended use(s) 
definitions and marketing claims. However, our findings show that 
in the real world, product definitions are often incomplete after early 
process phases, and there is less alignment between definitions than 
respondents deem preferable. Further analysis of findings indicates 
that inadequacies in the clarity of these product definitions (‘unclear 
definitions’) and in their completeness (‘missing data’), extend the 
time-frame for the achievement of regulatory approval and thus of 
market commercialization.
Khang and Moe (2008), advise on “the impact early phases have on 
later stages.” Like dominoes, the effect of tardiness in one step affects 
the next, several mini changes can accumulate to lead to a sizeable 
deviation by completion of all development stages. We suggest that 
delays in completing medical device product definitions and poor 
alignment between them, negatively impact MDD outcome. 
Study findings show that regulatory affairs respondents most strongly 
advocate and achieve early phase definitions of, and a very close alig-
nment between, intended use(s) and marketing claims descriptions, 
compared with other respondent roles. This must have implications 
on regulatory approval timelines. In our research, a regulatory affairs 
expert with fourteen years’ experience contends that “intended use(s) 
definitions must be made during concept development because pro-
duct design depends on the intended use(s).” The expert adds “this is 
commonly misinterpreted but the whole design and testing should 
be based on what the intended uses are as well as the design - you 
can have identical designs with different classifications based on your 
intended use - very few engineers get this.” This emphasizes the sig-
nificance of clear product definitions. Thus, we posit that regulatory 
affairs specialists are best placed to promote optimal regulation-con-
trolled product definitions outcomes, during MDD. 
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It is well-accepted that making alterations to product definitions 
becomes increasingly expensive as product development proceeds 
(Collyer et al., 2013; Fritz & Cardle, 2012). Thus, we suggest that our 
findings have implications for improved MDD, directing companies 
to specify and align intended use(s) and marketing claims definitions 
early, clearly and in full, to drive more successful MDD.   
It is noteworthy that the smallest teams of regulatory affairs specialists 
are associated with medium-sized companies (fig.2). Perhaps quality 
assurance respondents in medium-sized companies are expected to 
conduct regulatory as well as quality assurance functions (Tobin & 
Walsh, 2011). Thus, quality assurance respondents may be overburde-
ned which might explain the aforementioned trend for less alignment 
and later achievement of product definitions associated with the qua-
lity assurance role and medium-sized companies.  
5.2.2 Post-marketing surveillance
As explained elsewhere in this paper, the requirement for the medical 
device industry to monitor the performance of its marketed products is 
obligatory. The reason is to satisfy regulatory authorities that the medi-
cal devices remain useful and safe in the community where far greater 
numbers of people access and use them compared with limited users 
during clinical trials. As such, the industry might be expected to a) pla-
ce a high priority on conducting post-marketing surveillance and b) 
encourage the active participation of teams involved in regulation and 
customer contact, in gathering post-marketing feedback. 
Contrary to expectations, we find that a) senior management attaches 
a ‘very high’ level of importance to post-marketing surveillance ac-
tivities in less than 20% of cases. Instead, ‘speed to market’ is senior 
management’s leading priority. The emphasis on post-marketing sur-
veillance comes only 6th place in priority, and b) while marketing teams 
are best placed to gather post-marketing feedback because of their 
frequent and on-going direct contact with customers and users, they 
demonstrate a disappointing less than 50% involvement in the activity. 
We suggest this is a missed opportunity for the industry. First, we re-
commend that the industry should regard post-marketing surveillan-
ce more highly and conduct it more proactively so that potential pro-
blems become identified when they are on a small scale. In so doing, 
it could prevent the type of large-scale scandals mentioned earlier 
which not only jeopardize peoples’ health but also negatively impact 
a company’s reputation that can take years to rebuild. Secondly, such 
scandals have led to increasing calls for increased regulation of the in-
dustry to pre-empt such disasters (Kierkegaard & Kierkegaard, 2013). 
By taking a more proactive role in post-marketing surveillance, the 
industry could increase its control over the management of safety is-
sues and ameliorate calls for greater regulatory oversight. Moreover, 
it could provide useful information to MDD teams to feed into future 
product improvement and innovation plans.
Finally, by placing ‘speed to market’ and ‘return on marketing bud-
gets’ at higher priority levels than the pursuit of ‘post-marketing 
activities,’ senior management may be inadvertently creating con-
flict between marketing teams and regulatory affairs/quality assu-
rance teams. Since the future of medical device innovation calls for 
increasing cross-functional collaborations (Hede et al., 2013), this 
issue needs further examination. After all, improving rates of regula-
tory approval will contribute to greater speed to market!
5.3 Teams and MDD 
The research asked respondents during which phases in the MDD 
process do their respective teams become involved, and, arguably 
more importantly, how influential they believe their input is. Unex-
pectedly, we found that in approximately half of cases, marketing 
teams are not involved in the concept development phase while in 
even more cases, they are not involved in the design phase. The lite-
rature contends “it is shown that, in particular, the preparatory work 
[…] in the early phases of the NPD process […] are decisive for the 
success of new products” (Holger, 2002), which begs the question 
how organizations expect to make clear, unambiguous and timely 
product definitions if the experts who are expected to market these 
products are not present to provide input and have an impact on pro-
duct definition decisions. Indeed, 100% of marketing management 
respondents concur that marketing claims should be defined by the 
end of the design phase at the latest, which further highlights the 
questionable absence of marketing teams in a substantial number of 
cases, during early NPD phases. 
We examined the relationships, levels of trust and communication 
between cross-functional teams and enquired about the frequency of 
team meetings. In some cases, findings showed low levels of trust, 
lower levels of communication and infrequent cross-functional team 
meetings. These findings may explain our discovery of less collabo-
ration than expected between teams during the earliest and latest 
process phases. It may reflect the tensions we surmise exists between 
marketing teams and regulatory affairs/quality assurance teams due 
to senior management’s emphasis on ‘speed to market’ over ‘achie-
vement of regulatory approval.’ If emphasis is placed on improved 
collaboration between teams, it could foster improved relationships, 
engender higher levels of trust and enhance communication within 
and between teams, and drive earlier phase product definitions and 
later phase post-marketing surveillance activities, improving MDD 
(Cooper & Kleinschmidt, 2007). 
5.4 Senior management support for regulation
The literature advocates that commitment by senior management to 
innovation enhances NPD. We advocate that commitment by senior 
management to regulation will enhance MDD. We propose that senior 
management should exhibit this commitment to regulation in the same 
way it does to innovation. In summary, senior management should con-
tinually and consistently support regulatory authorities’ requirements by 
emphasizing the priority and value of regulatory compliance to emplo-
yees ahead of the expedition of products to market. Senior management 
should provide adequate resources to support regulatory goals, and de-
velop excellent relations with employees who manage regulation issues.  
Findings reveal that respondents are, in the main, satisfied with re-
sources toward regulation provided by senior management and that 
the best relationships of trust and communication exist between res-
pondent teams and senior management. This bodes well for regula-
tory management.
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However, lower levels of both trust and communication appear evi-
dent between regulatory affairs/quality assurance teams and marke-
ting teams. We have seen that ‘speed to market’ is perceived by our 
respondents to be the highest priority of senior management. Thus, 
achieving regulatory approval including support for post-marketing 
surveillance activities, competes with senior managements’ desire to 
reach the markets quickly. Gaining market access is seen as a respon-
sibility of marketing teams and may explain the poorer relationship 
and levels of trust we find between marketing teams and the other 
respondent teams. Marketing may feel that regulation holds back pro-
gression towards markets. Such findings may indicate that a gap exists 
in the knowledge of senior management about the interdependence 
between achieving regulatory approval and timely market access. We 
suggest senior management raises the priority level of ‘achieving re-
gulatory approval’ ahead of achieving ‘speed to market’ and encoura-
ges stronger alliances and co-operation between marketing, regula-
tory and quality assurance teams to expedite both regulatory approval 
rates and consequently commercialization.
Furthermore, the relatively low emphasis placed on post-marketing 
surveillance by senior management suggests a low appreciation for 
the potential contribution toward improved product development 
that is inherent in such feedback. A greater emphasis on post-mar-
keting surveillance should drive product innovation and overall cus-
tomer satisfaction.
5.5 Strategy for regulation
Most of the companies in our research sample purport to have a regu-
latory strategy and of these, three- quarters say that it also forms part 
of corporate strategy. Our findings show that where a regulatory stra-
tegy exists, most respondents believe it is clear and well communica-
ted. The study shows no findings of statistical significance between 
company size and the possession of a regulatory strategy. However, 
there is a statistically significant correlation in the association bet-
ween having a regulatory strategy and achieving on-time approval 
more frequently which leads us to recommend that all companies 
should strive to ensure a clear, well-communicated regulatory stra-
tegy exists in their organization. According to the literature in NPD, 
integration of the strategy within the corporate strategy can only fur-
ther advance successful MDD. 
5.6 A culture for regulation
It is no surprise that regulatory affairs specialists possess the greatest 
levels of knowledge on the subject of regulation. What is surprising 
is that only 45% of quality assurance respondents deem their regula-
tory knowledge to be “very good” and as many as 30% of marketing 
respondents report their knowledge at the lowest level. These findings 
suggest a disadvantage for companies in which the regulatory affairs 
position does not exist and where quality assurance personnel carry 
out regulatory and quality duties. The importance of and distinction 
between each of these separate roles is illustrated by Fritz and Card-
le (2012),  who say “Regulatory Affairs deals mostly with issues re-
lated to compliance. Quality Assurance encompasses the processes, 
procedures, and culture that permeate an organization — enabling it 
to consistently develop and produce high-quality […] products that 
will meet or exceed regulatory requirements.” In our study, while 
we cannot be sure that quality assurance respondents did not work 
alongside regulatory affairs colleagues in their respective organi-
zation, it seems unlikely. During survey dispatch, we requested the 
identity of regulatory affairs personnel. If we received information 
saying the regulatory affairs role was non-existent, we were advised 
that someone in quality assurance was in charge of regulatory affairs 
duties. Nevertheless, our results suggest a greater knowledge capa-
city for regulation in the largest companies where regulatory affairs 
teams are at their biggest. In organizations where quality assurance 
employees have direct and sole responsibility for maintaining regula-
tory compliance and quality assurance, these specialists may be under 
significant work-pressure. This may explain our findings of greater 
levels of dissatisfaction among quality assurance respondents regar-
ding regulation-related resources provided to them, team sizes, and 
the lower regulatory compliance performance seen associated with 
quality assurance versus regulatory affairs specialists.
We cite a lower level of regulatory knowledge among marketing res-
pondents. Perhaps this reflects a gap in knowledge of the value mar-
keting teams could offer NPD, and perhaps it explains the absence of 
marketing teams during concept and design development phases in 
a high number of cases, which a stronger culture for regulation could 
help redress. 
Interestingly, we reveal a low level of respondent knowledge regarding 
regulatory-related performance data; the extant literature advises that 
employees should have knowledge of performance results to improve 
their performance. We suggest that MDD would benefit from greater 
stakeholder knowledge of regulatory performance outcome measures. 
The knowledge amongst respondents that regulation impacts a 
product’s safety and reliability, appears to be well communicated to 
respondent. This finding reflects a culture that associates regulation 
with good practice. It is interesting that only 27.3% consider that re-
gulation has its “greatest impact” or its “second greatest impact” on 
‘speed to market.’ This finding suggests that respondents do not feel 
that regulation hinders speed of market access. However, it may also 
suggest that the majority of respondents are ignorant of the direct 
connection between acquisition of regulatory approval and market 
access. In other words, stakeholders may not fully appreciate that if 
regulatory approval is achieved efficiently through a wholehearted 
company approach and employee commitment toward regulation, it 
will positively influence the speed of market access. This finding may 
be the most significant one of our study. 
Consequently, a culture that would encourage embracing regulation 
has the potential to improve outcomes of all the measures in our stu-
dy. A culture of regulation would insist on a number of conditions; 
first, a strategy for regulation supported by the corporate strategy; 
second, senior management displaying very strong commitment to 
regulation including promotion of regulatory knowledge training, 
dissemination of regulatory performance data to employees and 
encouragement of high levels of communication on regulatory mat-
ters; third, teams fostering cross-functional collaborations including 
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marketing teams’ involvement during earlier product development 
phases to confirm product definitions and drive closer alignment of 
definitions leading to more rapid commercialization. Furthermore, 
a stronger culture for regulation would encourage marketing teams, 
in particular, to take a more proactive approach in gathering post-
marketing surveillance information that would improve compliance 
and could advance improved medical device innovation outcomes. 
As Medina et al. (2013) explain, “the regulatory requirements […] 
play a substantive role in shaping activities and decisions in the [de-
velopment] process.” Consequently, regulatory requirements must 
always be at the forefront of all considerations regarding MDD. 
6 Conclusions and Recommendations
Regulatory strategies are built around the classification of devices ac-
cording to risk, so, as medical devices become increasingly elaborate 
and complex, regulatory strategy demands will grow (Holger, 2002; 
Tobin & Walsh, 2011). Tensions between NPD and regulatory com-
pliance are therefore likely to become increasingly salient in MDD. 
Also, new collaborations will grow between multidisciplinary teams 
and will require nurturing because of divergent and competing objec-
tives. This is a highly complicated scenario that companies must learn 
to navigate to enable timely market entry and organizational survival. 
Our findings expose serious gaps in the management of medical 
device innovation. We emphasise the need for management within 
the industry to put a stronger emphasis on regulatory management 
over speed to market; incorporate regulatory strategy into the cor-
porate agenda; encourage improved relationships and collaborations 
between multidisciplinary teams during MDD, particularly in the 
earliest process phases of development when product definitions are 
being determined; actively gather and share post-marketing feedback; 
and encourage knowledge of regulatory performance amongst key 
stakeholders; all to enable more effective and efficient MDD within 
its regulatory framework. 
If our work exposes nothing more than the direct influence regula-
tory management has upon the speed at which new medical devices 
can enter and continue to thrive in their markets, it will have been 
worthwhile. We conclude by recommending that the medical device 
industry adopts an organizational culture for regulation by “embra-
cing regulation” throughout all MDD activities. 
7 Contribution
This research is significant first because it is built on real world empi-
rical data and to our knowledge no comparable data exists; we believe 
our study within the medical device industry based in Ireland is the 
first and largest of its kind. Given the size and significance of this in-
dustry in Ireland and globally, this in itself makes our contribution 
meaningful. Our work contributes to the study and practice of MDD. 
It identifies factors associated with expediting MDD and exposes key 
issues requiring further research into the management MDD. Ove-
rall, it expands our knowledge and deepens our understanding in an 
area of mutual benefit to our economy, the medical device industry, 
medical professionals and the public at large. 
References
Baker, W. E., & Sinkula, J. M. (2007). Does Market Orientation Fa-
cilitate Balanced Innovation Programs? An Organizational Learning 
Perspective. Journal of Product Innovation Management, 24(4), 316-
334. doi:10.1111/j.1540-5885.2007.00254.x
Collyer, K., Bakal, M. R., & Verma, P. (2013). Three steps to rapid de-
velopment of high-quality medical devices within regulatory norms. 
Cooper, R. G., & Kleinschmidt, E. J. (1995). Benchmarking the firm’s 
critical success factors in new product development. Journal of Pro-
duct Innovation Management, 12(5), 374-391. doi:http://dx.doi.
org/10.1016/0737-6782(95)00059-3
Cooper, R. G., & Kleinschmidt, E. J. (2007). Winning businesses in 
product development: The critical success factors. Research Technolo-
gy Management, 50(3), 52-66. 
Creswell, J. W. (2009). Editorial: Mapping the Field of Mixed Methods 
Research (Vol. 3, pp. 95-108).
De Waal, G. A., & Knott, P. (2010). Process and strategy influences on 
product development performance in New Zealand. Small Enterprise 
Research, 17(2), 193-206. doi:10.5172/ser.17.2.193
Dhruva, S. S., & Redberg, R. F. (2012). Medical Device Regulation: 
Time to Improve Performance. PLoS Medicine, 9(7), 1-2. doi:10.1371/
journal.pmed.1001277
Dillman, D. A. (2007). Mail and internet surveys : the tailored design 
method (2nd, 2007 update with new internet, visual, and mixed-mode 
guide. ed.). Hoboken, N.J.: Hoboken, N.J. : Wiley.
Dodgson, M., Gann, D., & Salter, A. (2008). The management of tech-
nological innovation : strategy and practice (New ed., rev. and updated. 
ed.). Oxford New York: Oxford New York : Oxford University Press.
Easterby-Smith, M., Thorpe, R., & Jackson, P. (2008). Management re-
search (3rd ed.). Los Angeles. London: Los Angeles. London : SAGE.
Engberg, R., & Altmann, P. (2015). Regulation and Technology In-
novation: A Comparison of Stated and Formal Regulatory Barriers 
throughout the Technology Innovation Process. Journal of Technology 
Management & Innovation, 10(3), 85-91. 
Fink, A. (2013). How to conduct surveys : a step-by-step guide (5th ed.). 
Thousand Oaks, Calif.: Thousand Oaks, Calif. : SAGE Publications.
Fritz, M., & Cardle, A. (2012). The foundations of pharmaceutical 
compliance for beginners. (3639). Retrieved May 2016, from Pharma-
ceutical Compliance Monitor http:/www.pharmaceuticalcompliance-
monitor.com/the_foundations_of_pharmaceutical_compliance_for_
beginners/3639/accessedMay2016
Gregory, D., Curfman, G. D., & Redberg, R. F. (2011). Medical de-
vices--balancing regulation and innovation. New England Journal of 
Medicine, 365(11), 975-977. 
J. Technol. Manag. Innov. 2017. Volume 12, Issue 1
ISSN: 0718-2724. (http://jotmi.org)
Journal of Technology Management & Innovation © Universidad Alberto Hurtado, Facultad de Economía y Negocios. 38
Hede, S., Nunes, M. J. L., Ferreira, P. F. V., & Rocha, L. A. (2013). 
Incorporating sustainability in decision-making for medical device 
development. Technology in Society, 35(4), 276-293. doi:http://dx.doi.
org/10.1016/j.techsoc.2013.09.003
Holger, E. (2002). Success Factors of New Product Development: A 
Review of the Empirical Literature. International Journal of Manage-
ment Reviews, 4(1), 1. 
IMDA. (2016). Irish Medical Devices Association Membership Di-
rectory.   Retrieved from http://www.imda.ie/Sectors/IMDA/IMDA.
nsf/vPages/Membership~membership-directory!OpenDocument
Jonas, D. (2010). Empowering project portfolio managers: How ma-
nagement involvement impacts project portfolio management per-
formance. International Journal of Project Management, 28(8), 818-
831. doi:10.1016/j.ijproman.2010.07.002
Khang, D. B., & Moe, T. L. (2008). Success criteria and factors for 
international development projects: A life‐cycle‐based framework. 
Project Management Journal, 39(1), 72-84. doi:10.1002/pmj.20034
Khurana, A., & Rosenthal, S. R. (1998). Towards Holistic “Front 
Ends” In New Product Development. Journal of Product Innovation 
Management, 15(1), 57-74. doi:10.1111/1540-5885.1510057
Kierkegaard, S., & Kierkegaard, P. (2013). Danger to public health: 
Medical devices, toxicity, virus and fraud. Computer Law and Se-
curity Review: The International Journal of Technology and Practice. 
doi:10.1016/j.clsr.2012.11.006
Kumar, S., & Addie, H. S. (2006). The Hexopater TM , from birth to 
market: innovative product development challenges. Journal of Engi-
neering Design, 17(3), 271-289. doi:10.1080/09544820500274282
Medina, L. A., Kremer, G. E. O., & Wysk, R. A. (2013). Supporting 
medical device development: a standard product design process mo-
del. Journal of Engineering Design, 24(2), 83-119. doi:10.1080/095448
28.2012.676635
Morgan, N. (2012). Marketing and business performance. Official 
Publication of the Academy of Marketing Science, 40(1), 102-119. 
doi:10.1007/s11747-011-0279-9
Pallant, J. (2010). SPSS survival manual a step by step guide to data 
analysis using SPSS (4th ed.). Maidenhead [etc.]: Maidenhead : Open 
University Press/McGraw-Hill.
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